Literature DB >> 3907000

Prevention of fever and gram negative infection after open heart surgery by antiendotoxin.

R Freeman, F K Gould.   

Abstract

Naturally occurring preoperative antibody to enteric Gram negative bacilli (Escherichia coli agglutinins or antiendotoxin, or both) in 30 patients who had had open heart surgery was associated with a significantly lower incidence of early postoperative fever and postoperative Gram negative infection than occurred in 56 patients without preoperative antibodies. The protective effect was shown to be associated with antiendotoxin rather than antibody to the somatic antigen of the bacteria. Active or passive immunisation of patients having open heart surgery against endotoxin is likely to decrease significantly the morbidity after cardiopulmonary bypass.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3907000      PMCID: PMC1020563          DOI: 10.1136/thx.40.11.846

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  7 in total

1.  Treatment and prevention of intravascular coagulation with antiserum to endotoxin.

Authors:  A I Braude; H Douglas; C E Davis
Journal:  J Infect Dis       Date:  1973-07       Impact factor: 5.226

2.  Host-parasite interaction in patients with infections due to Escherichia coli. II. Serologic response of the host.

Authors:  K L Vosti; A S Monto; L A Rantz
Journal:  J Lab Clin Med       Date:  1965-10

3.  Rises in antibody to enteric gram negative bacilli after open heart surgery: a possible mechanism for postoperative pyrexia.

Authors:  R Freeman; F K Gould
Journal:  Thorax       Date:  1985-07       Impact factor: 9.139

4.  Pyrexia following open heart surgery. The role of bacterial infection.

Authors:  E D de Villota; G Barat; F Astorqui; D Dámaso; F Avello
Journal:  Anaesthesia       Date:  1974-09       Impact factor: 6.955

5.  Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin.

Authors:  E Lachman; S B Pitsoe; S L Gaffin
Journal:  Lancet       Date:  1984-05-05       Impact factor: 79.321

6.  Antibody to cell wall glycolipid of Gram-negative bacteria: induction of immunity to bacteremia and endotoxemia.

Authors:  A I Braude; E J Ziegler; H Douglas; J A McCutchan
Journal:  J Infect Dis       Date:  1977-08       Impact factor: 5.226

7.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli.

Authors:  E J Ziegler; J A McCutchan; J Fierer; M P Glauser; J C Sadoff; H Douglas; A I Braude
Journal:  N Engl J Med       Date:  1982-11-11       Impact factor: 91.245

  7 in total
  6 in total

1.  Searching for the etiology of systemic inflammatory response syndrome: is SIRS occult endotoxemia?

Authors:  Joseph A Carcillo
Journal:  Intensive Care Med       Date:  2006-02-01       Impact factor: 17.440

2.  Serological relationships between Escherichia coli and Salmonella smooth- and rough-mutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies.

Authors:  G R Barclay; B B Scott
Journal:  Infect Immun       Date:  1987-11       Impact factor: 3.441

3.  Serum immunoglobulins to endotoxin core glycolipid: acute leukaemia and other cancers.

Authors:  S K Jackson; J Parton; G Shortland; J M Stark; E N Thompson
Journal:  Arch Dis Child       Date:  1990-07       Impact factor: 3.791

4.  Preparation and preclinical evaluation of a novel liposomal complete-core lipopolysaccharide vaccine.

Authors:  E Bennett-Guerrero; T J McIntosh; G R Barclay; D S Snyder; R J Gibbs; M G Mythen; I R Poxton
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

5.  Sequential anti-core glycolipid immunoglobulin antibody activities in patients with and without septic shock and their relation to outcome.

Authors:  M Nys; P Damas; L Joassin; M Lamy
Journal:  Ann Surg       Date:  1993-03       Impact factor: 12.969

6.  All accessible epitopes in the Salmonella lipopolysaccharide core are associated with branch residues.

Authors:  N A Nnalue
Journal:  Infect Immun       Date:  1999-02       Impact factor: 3.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.